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Abstract
Background: Airway inflammation is a feature of many respiratory diseases and
there is a need for newer, more effective anti-inflammatory compounds. The
aim of this study was to develop an   human lung explant model whichex vivo
can be used to help study the mechanisms underlying inflammatory responses
and which can provide a tool to aid drug discovery for inflammatory respiratory
diseases such as asthma and COPD.
Method: Parenchymal lung tissue from 6 individual donors was dissected and
cultured with two pro-inflammatory stimuli, lipopolysaccharide (LPS) (1 µg/ml)
and interleukin-1 beta (IL-1β) (10 ng/ml) in the presence or absence of
dexamethasone (1 µM).  Inflammatory responses were assessed using
Luminex analysis of tissue culture supernatants to measure levels of 21
chemokines, growth factors and cytokines.
Results: A robust and reproducible inflammatory signal was detected across all
donors for 12 of the analytes measured following LPS stimulation with a modest
fold increase (<2-fold) in levels of CCL22, IL-4, and IL-2; increases of 2-4-fold
in levels of CXCL8, VEGF and IL-6 and increases >4-fold in CCL3, CCL4,
GM-CSF, IL-10, TNF-α and IL-1β.  The inflammatory signal induced by IL-1β
stimulation was less than that observed with LPS but resulted in elevated levels
of 7 analytes (CXCL8, CCL3, CCL4, GM-CSF, IL-6, IL-10 and TNF-α).  The
inflammatory responses induced by both stimulations was supressed by
dexamethasone for the majority of analytes.
Conclusions: These data provide proof of concept that this   human lungex vivo
explant model is responsive to inflammatory signals and could be used to
investigate the anti-inflammatory effects of existing and novel compounds.  In
addition this model could be used to help define the mechanisms and pathways
involved in development of inflammatory airway disease.
Abbreviations: COPD: Chronic Obstructive Pulmonary Disease; ICS: inhaled
corticosteroids; LPS: lipopolysaccharide; IL-1β: interleukin-1 beta; PSF:
penicillin, streptomycin and fungizone
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Introduction
Obstructive lung diseases such as asthma and Chronic Obstruc-
tive Pulmonary Disease (COPD) are characterised by inflamma-
tion which can affect both large and small airways1. Treatment 
options for these inflammatory lung diseases remain limited 
and not all patients respond to the most commonly used medi-
cines, including inhaled corticosteroids (ICS) and β-2 adrenergic 
receptor agonists2–5. There is a need for new treatments for both 
asthma and COPD, and particularly for approaches which target 
inflammation4, especially in the small airways, which have been 
increasingly recognised as an important site of inflammation6,7.
Whilst there have been some studies which have used ex vivo 
cell or tissue to look at inflammatory responses, the lack of a robust 
human tissue system has to some extent hindered pre-clinical 
drug development and mechanistic studies in these diseases. 
Animal models have long been used to try and predict efficacy in 
human disease but findings in animal models often fail to predict 
responses in humans. This is particularly true for diseases such 
as asthma and COPD for which animal models are only able to 
recapitulate some of the features of the human disease2,8,9. A human 
tissue explant model would therefore complement those in vivo 
mouse models which currently exist.
Preliminary data exist demonstrating that ex vivo human lung 
tissue models can be used to study the effect of allergens and 
other inflammatory stimuli on selected cytokine responses10,11. 
Our aim was to develop a reproducible human lung tissue explant 
model which could be used for target validation and to help 
investigate mechanisms underlying inflammation relevant to 
airway disease.
In this study we assessed human lung tissue explants ex vivo to 
define inflammatory signalling using multiplex cytokine assays. 
In order to elicit an inflammatory response in human lung tissue 
bacterial lipopolysaccharide (LPS) and interleukin-1 beta (IL-1β) 
were used12–14. We defined the cytokine and chemokine signature 
of this tissue in response to these stimuli and also provide data 
on the reproducibility of this model by assessing responses to 
21 chemokines, growth factors and cytokines. To determine the 
usefulness of the model to identify anti-inflammatory mechanisms 
we also examined the effect of potential inhibitory responses using 
dexamethasone.
Methods
Human parenchymal lung tissue was obtained from the 
Nottingham Research Biorepository from patients undergoing 
lung resection surgery at Nottingham University Hospitals, UK. 
Written consent was obtained from all patients and the study 
was approved by North West 7 REC – Greater Manchester 
Central (ethics reference 10/H1008/72). The patient demo-
graphics of the six donor subjects used in the current study are 
shown in Supplementary table 1. The mean age of donors was 
75.5 ± 10.5 years (4 females and 2 males). In total, three indi-
viduals were ex-smokers (stopped ≥ 3 years), two were recent 
smokers (stopped ≤ 3 years) and one was never a smoker. Three 
subjects had spirometry suggesting the presence of COPD.
Lung tissue was dissected into 30–100 mg (wet weight) pieces 
and incubated for 24h in RPMI 1640 (with 2.05 mM L-glutamine 
and 25 mM HEPES) (Sigma, 51536C) containing Antibiotic 
Antimycotic Solution (PSF, penicillin, streptomycin and fun-
gizone) (Sigma, A5955). Following initial incubation, media was 
replaced, and following the addition of LPS or IL-1β (1 µg/ml or 
10 ng/ml respectively) or vehicle controls in the presence or 
absence of 1 µM dexamethasone, the tissue was incubated for a 
further 24h, followed by the collection of supernatants. All experi-
mental conditions were prepared in duplicate.
We designed a custom multiplex panel of 21 Luminex assays to 
provide comprehensive information on the protein secretory 
profile of the human lung tissue. This panel was designed to 
encompass the main inflammatory pathways activated in the 
lung, including chemokine, cytokine and growth factor pathways 
(Supplementary table 2).
Luminex assays (supplied by R&D, product code LXSAHM) 
were performed according to the manufacturer’s recommenda-
tions using a custom Magnetic Luminex Screening Assay with a 
Human Premixed Multi-Analyte Kit (R&D systems). Each dupli-
cate supernatant from the lung tissue explant experiment was 
assayed in duplicate.
Results were normalised using wet tissue weights in individual 
experiments and data were normalised to maximal inflamma-
tory stimulus level (i.e. LPS or IL-1β, 100%) in each experiment 
prior to combining data. Statistical analysis was performed using 
ANOVA and post-hoc Dunnett’s multiple comparisons test. 
Statistical analysis was performed using GraphPad Prism software 
(Version 6, GraphPad Software Inc.).
Ethics approval and consent statement
Written consent was obtained from all patients and the study 
was approved under ethics reference 10/H1008/72, 12/SC/0526 
and 08/H0304/56+5. All samples were obtained and research 
conducted under the approval of the Nottingham Health Science 
Biobank, Arden Tissue Bank and Papworth Hospital Research 
Tissue Bank. Written consent was obtained from all patients to 
publish research findings obtained from the use of patient samples 
under the approval of the Research Tissue Banks.
Results
Using the multiplex approach, 12 of the 21 inflammatory analytes 
assayed generated quantifiable signals in the Luminex assay across 
all donors following 24h incubation under baseline (unstimulated) 
conditions (Figure 1 and Supplementary table 3). The analytes 
detected were a range of chemokines including CCL3, CCL4, 
cytokines including IL-6, CXCL8 and several growth factors 
including VEGF (Figure 1 and Supplementary table 3).
With the exception of IL-2, there was a significant induction 
of levels of all analytes detectable following LPS stimulation 
(Figure 1A and 1B). The fold stimulation within donor sam-
ples was reasonably reproducible for CXCL8 (3.5-fold), CCL3 
(~33-fold), CCL4 (~18-fold), CCL22 (1.6-fold), GM-CSF 
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(~25-fold) and VEGF (1.8-fold) (Figure 1A). There was also a sig-
nificant cytokine induction in the tissue, characterised by elevated 
levels of IL-4 (1.8-fold), IL-6 (3.8-fold), IL-10 (~96-fold), TNF-α 
(~600-fold), IL-1β (~30-fold) and IL-2 (1.3) (Figure 1B). The 
absolute values (as opposed to the fold stimulations) varied to 
some extent across donors even when corrected for tissue wet 
weight.
From the 12 analytes that exhibited a significant LPS driven 
response, pre-treatment with dexamethasone (1 µM) attenuated 
this response by >50% for 9 of the analytes. Dexamethasone was 
unable to significantly attenuate the stimulation of CCL22 or 
IL-2 production, suggesting this induction was steroid insensitive 
(Figure 1A and 1B).
IL-1β was also able to induce an inflammatory response in 
the human lung tissue, however both the magnitude and diversity 
of the responses observed across the 21 analytes was diminished 
in comparison to LPS. IL-1β stimulated production of 7 of the 
analytes, and this response was attenuated by dexamethasone 
treatment for 6 of these targets (Figure 1C and 1D). The great-
est level of induction was observed for TNF-α (~35-fold), fol-
lowed by GM-CSF (~32-fold), IL-10 (~10-fold), CCL3 (~5-fold), 
CCL4 (2.3-fold), CXCL8 (2.3-fold) and IL-6 (1.8-fold) (Figure 1C 
and 1D). Treatment with dexamethasone attenuated these inflam-
matory responses to varying degrees, with the greatest reduction 
being TNF-α (~70%), although the actual concentration of this 
analyte was low (~0.8 pg/ml/mg tissue) compared to the LPS 
stimulated sample (~30 pg/ml/mg tissue) (Supplementary table 3). 
Figure 1. The secretory profile of ex vivo human lung tissue following LPS and IL-1β stimulation. LPS significantly induced the release 
of 12 analytes in cultured lung tissue explants, including chemokines and other factors (e.g. growth factors) (A) and cytokines (B). For 10 of 
these analytes, this response was attenuated with dexamethasone treatment. Results were normalised using tissue mass and data were then 
normalised to the LPS stimulation (100%) from each donor and are presented as mean (±SEM, n=6). IL-1β significantly induced the release 
of 7 analytes in cultured lung tissue explants, including chemokines and other factors (C) and cytokines (D). For 6 of these analytes, this 
response was attenuated with dexamethasone treatment. Results were normalised using wet tissue mass and data were then normalised to 
the IL-1β stimulation (100%) from each donor and are presented as mean (±SEM, n=4). Due to limited tissue availability for two donors, it was 
not possible to obtain tissue from all six donors for the IL-1β experiments.
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Attenuation of the inflammatory response was >35% for 
the remaining 5 analytes, for which statistically significant 
reductions were seen for IL-6, CCL3, GM-CSF, CXCL8 and 
IL-10. Although there was a 33% reduction in CCL4 following 
treatment with dexamethasone, this was not statistically significant 
(Figure 1C and 1D).
LPS induced a more pronounced inflammatory response than 
IL-1β when comparing absolute concentrations of the ana-
lytes measured (Supplementary table 3). Figure 2 allows direct 
comparisons to be made between the two pro-inflammatory 
stimuli, and provides insight into the degree of inter-donor 
variability observed in the model. Some donor variation was 
apparent for both CXCL8 and CCL3 at both basal levels and fol-
lowing stimulation (Figure 2A–D).
In order to further explore the degree of variability in responses, 
we measured CXCL8 production in tissue obtained from 5 addi-
tional subjects. The mean basal levels of CXCL8 produced (total of 
n=11 donors) were 1941 (range 232–7927) pg/ml/mg tissue 
and the fold stimulation observed with LPS was 3.9-fold (range 
2.2–12.7).
Figure 2. Comparison of concentration of CXCL8 and CCL3 following LPS and IL-1β stimulation and dexamethasone treatment. 
LPS and IL-1β both induced an inflammatory response in ex-vivo lung tissue, although the response with LPS was greater than with IL-1β. 
Compared to the IL-1β stimulation, there was an overall 1.8-fold increase in CXCL8 concentration (A and B) following LPS stimulation and an 
overall 11-fold increase in levels of CCL3 (C and D).
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Dataset 1. LPS raw data
http://dx.doi.org/10.5256/f1000research.10961.d157792
Luminex raw data for LPS stimulated tissue (Donors n=6).
Dataset 2. IL-1b raw data
http://dx.doi.org/10.5256/f1000research.10961.d157794
Luminex raw data for IL-1b stimulated tissue (Donors n=4).
Discussion
There is a need for well-characterised human lung tissue models 
to assess pro and anti-inflammatory responses in the lung and to 
help with target validation during the drug development process. 
We have therefore developed an explant model using ex-vivo human 
lung tissue to investigate the inflammatory responses induced using 
two physiologically relevant stimuli. We characterised responses 
using Luminex assays to simultaneously permit analysis of a range 
of cytokines and other mediators. We chose LPS as a stimulus 
to mimic bacterial infection and IL-1β as a more selective pro- 
inflammatory signal. The data presented demonstrate that reason-
ably reproducible responses can be obtained in this model despite 
there being an inevitable element of heterogeneity in the tissue 
obtained from each donor. We also used pre-treatment with dexam-
ethasone as proof of concept to identify anti-inflammatory effects 
in this model. The reduction in inflammatory mediator responses 
observed after dexamethasone pre-treatment support the use of this 
model for investigation of potentially anti-inflammatory effects of 
novel compounds in the human lung.
Models currently used in airway disease research have limita-
tions. For instance, rodent in vivo models have been heavily relied 
upon and whilst these can provide useful mechanistic insights they 
do not always translate well when assessing efficacy in human 
disease8,9. Human tissue based models should enhance mechanistic 
and pre-clinical studies and will hopefully prove more predictive 
for target validation for diseases such as asthma and COPD.
We describe here the inflammatory secretory profiles obtained 
using pro-inflammatory stimuli LPS and IL-1β in this model. 
Both induced release of a range chemokines, cytokines and 
growth factors. As would be expected, the magnitude of effect was 
greater with LPS than with IL-1β. Appropriate vehicle controls 
were included in all experiments and did not produce responses. 
Some variability in both basal and stimulated levels of mediators 
was seen between donors, although within donor reproducibility 
of responses was generally good (Figure 2).
Bacterial infection and exacerbation are common in COPD and 
asthma patients12,13,15–17. The broad secretory profile that is obtained 
following LPS stimulation supports its role as a broad activator of 
intra-cellular signalling pathways. The responses we observed in 
the ex vivo model broadly mirror observations in the clinical set-
ting; for example, IL-6, CXCL8 and TNF-α are elevated following 
COPD exacerbation in induced sputum or bronchoalveolar lavage 
samples15–17. The data presented here also agree with previous work 
assessing cytokine responses in a less extensively characterised 
human lung tissue model, in which TNF-α, IL-1β, IL-6, CXCL8 
and IL-10 production was observed following LPS exposure or fol-
lowing influenza virus induced inflammation18,19.
IL-1β stimulation resulted in an induction of mediators where 
only 7 of the analytes measured increased by significant levels, 
and the magnitude of effect was lower than that seen with LPS 
stimulation, reflecting the more selective induction of signalling 
pathways with this agonist.
There is a pressing need for the development of new human 
disease models, in particular those which help reduce the need 
for animal models2,8,20. There are intensive efforts to reconstitute 
the key components of the airway to generate clinically relevant 
in vitro models to be used in basic research and compound eval-
uation, including lung-on-a chip21, dendritic cell-epithelium- 
fibroblast scaffolds22 and differentiated epithelial cell layers23. 
These approaches have both strengths and weaknesses; applica-
bility to scale up is a strength but none are fully representative of 
an in vivo human lung. One of the advantages of the lung explant 
model over models such as air liquid interface culture of epithe-
lial cells is maintenance of in vivo cell architecture without the 
need to induce differentiation in culture. Another approach that 
is growing in popularity and shares many of the advantages of an 
ex vivo tissue model is precision cut lung slices which provide a 
scaled model of the explant approach24,25. However, preparing 
precision cut lung slices from human tissue is technically much 
more difficult than from mouse tissue, and for the study of inflam-
matory approaches (as opposed to contractile responses) it offers 
no real advantages.
It is also possible that the use of a human tissue based approach 
could reduce the use of animals in target validation and overcome 
some of the obstacles and pitfalls faced when progressing from 
pre-clinical studies with animals to human trials2. However, it is 
also important to note that there are limitations; including limited 
accessibility to human tissue, the relatively heterogeneous nature of 
resection samples, and natural donor variation in responses.
Conclusions
In summary, we have demonstrated proof of concept that an 
ex vivo human lung tissue explant model can be used to mimic 
airway inflammation and provide low/medium throughput screen-
ing of anti-inflammatory properties of candidate drugs for the 
treatment of airway disease. This model should also help with 
target validation and reduce the reliance on animal models, thus 
reducing animal usage in the drug development process.
Data availability
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small pieces of human lung tissue and cultures them in a standard growth media for periods of up to 24
hours. Media is removed and then can be used for downstream assays. In this case media was used in a
custom Luminex assay to detect a range of inflammatory mediators.
The results suggest that the model allows for the detection if secretion of 12/21 analytes chosen and
shows that secretion of these was modified by inclusion of the pro-inflammatory mediators, bacterial LPS
and interleukin beta into the media.
This preliminary data suggests that this type of model could be further developed and may become a
valuable tool for pulmonary research.
The current data shows how there is a high level of variability between different explants, both in terms of
basal and stimulated levels. The reasons for this will need to be explored. Does it represent true variability
between different donors or could it be due to the way in which individual donor explants are generated?
Maybe the size of each tissue fragment will have a significant influence on responses?
It will also be helpful to explore the tissue viability and to investigate extending the time frame of the
explant cultures? Again perhaps tissue fragment size will be an important variable.
Overall, the data provide a useful primer to the further development of lung tissue explants as a research
tool.
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This interesting report describes the use of human lung tissue explants as an   model to studyin vitro
responses to various proinflammatory stimuli. The authors showed that the model can be cultured for 24
hr and retains responsiveness to LPS and IL-1β with the production of different cytokines and growth
factors. Interestingly, the proinflammatory potential of cultured human lung tissue explants can still be
modulated by dexamethasone, suggesting that the model would be ideal to test novel anti-inflammatory
drugs. Overall the manuscript is clearly written and data are novel. There are some minor points that need
clarifications.
 
It would important to state how tissue viability was assessed following the 2 days culture
 
Please also provide, if possible, some representative picture of the histology of human lung tissue
explants before and following the 2 day culture
 
It would better to express the data in Figure 1 as net cytokine increase rather than % of LPS. 
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